Pharma BD Deal Intelligence
A $500M upfront, up-to-$1.2B licensing deal that gave Sanofi exclusive commercial rights to Novavax's adjuvanted COVID-19 vaccine. A capital lifeline for Novavax, though the shrinking COVID-19 vaccine market caps the upside for Sanofi.
Novavax strikes $1.2 billion deal with Sanofi in major turnaround after pandemic-era decline in COVID vaccine demand.
Sanofi keeps Novavax afloat with $1.2B bet on its vaccine platform for COVID-19 and flu-COVID combination vaccine development.
Sanofi paid Novavax $500 million upfront and promised up to $700 million in development, regulatory and launch milestones.
Source summaries from our enrichment pipeline; follow links for originals.
All 8 sources with sentiment breakdown →
Sanofi licensed Novavax's adjuvanted COVID-19 vaccine for exclusive commercialization rights, paying $500M upfront in a deal worth up to $1.2B.
The adjuvanted COVID-19 vaccine (NVX-CoV2373, Nuvaxovid, licensed by Sanofi from Novavax) is a recombinant spike protein with Matrix-M adjuvant, positioned as the non-mRNA alternative in a market dominated by mRNA platforms. mRNA vaccines (dominant MOA): Comirnaty (tozinameran, BNT162b2, Pfizer/BioNTech) and Spikevax (elasomeran, mRNA-1273, Moderna) collectively hold the overwhelming majority of global COVID-19 vaccine share; Pfizer reported Comirnaty 2023 revenues of approximately $11.2B and Moderna reported Spikevax 2023 revenues of approximately $6.7B, both down sharply from peak years. Updated 2024-2025 formulations target KP.2 (JN.1 sublineage). Adjuvanted recombinant protein (Novavax/Sanofi's MOA class): Novavax's Nuvaxovid is the only authorized recombinant-protein COVID-19 vaccine in the US/EU, providing a differentiation option for mRNA-hesitant or allergy-intolerant patients. Viral vector: Janssen/J&J's Ad26.COV2.S was discontinued in the US in 2023; AstraZeneca's Vaxzevria was withdrawn globally in 2024. Inactivated whole-virion: CoronaVac (Sinovac) and BBIBP-CorV (Sinopharm) remain in use internationally but not US/EU. Sanofi-GSK's own Vidprevtyn Beta (adjuvanted recombinant) is EMA-authorized but commercially marginal. The Sanofi-Novavax licensing thesis relies on pandemic contingency contracts and the non-mRNA niche (estimated <5% global share) rather than head-to-head mRNA displacement.
Sanofi paid $500M upfront for co-exclusive COVID-19 vaccine commercialization rights.
Nuvaxovid transferred to Sanofi. BLA approved by FDA May 2025. $175M approval milestone + $50M in transfer milestones paid.
Sanofi reported positive Phase 1/2 data for its influenza-COVID-19 combination programs (built on Novavax's adjuvanted COVID antigen), stating the data support a high probability of demonstrating non-inferiority in Phase 3. Novavax remains eligible for up to $350M in combo Phase 3 development and launch milestones.
Novavax recognized $49M of Sanofi revenue in Q1 2026 (upfront amortization, milestones, royalties, transition-services reimbursement). Sanofi to lead 2026-2027 COVID-season commercial activities in select markets including the US; Novavax still eligible for a $75M technology-transfer milestone plus combo and Matrix-M milestones.
Nuvaxovid approved (US BLA, 2025) and EU+US marketing authorizations transferred to Sanofi (Oct/Nov 2025). $225M in milestones earned in FY2025; partnership cadence continued into 2026 ($49M Sanofi revenue in Q1). Flu-COVID combination programs posted positive Phase 1/2 data in Dec 2025 and are advancing toward Phase 3, keeping up to $350M of combo milestones plus a $75M tech-transfer milestone in play. Thesis intact: milestones flowing, optionality expanding.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Sanofi SA / Novavax Inc. (this deal) | 2024 | $1.2B | 51 |
| Sanofi SA / Regeneron Pharmaceuticals, Inc. | 2007 | $1.0B | 97 |
| Sanofi SA / Synthelabo S.A. | 1998 | $11.0B | 84 |
| Sanofi SA / Genzyme Corporation | 2011 | $20.1B | 84 |
| Sanofi SA / Amunix Pharmaceuticals Inc. | 2021 | $1.2B | 76 |
| Sanofi SA / Genzyme Corporation | 2010 | $18.5B | 75 |
| Sanofi SA / Translate Bio Inc. | 2018 | $805M | 73 |
← Browse all deals · How we score deals
More: 2024 deals · Sanofi SA deals · Infectious Disease deals